It was shown that Tim-3 expression significantly decreased after CR compared to that in the initial diagnosed AML patients (P=0.01) (Figure 2), suggesting that high levels of Tim-3 expression on blasts in AML may enhance the chemotherapy sensitivity of AML patients. Here, HAVCR2 is linked to acute myeloid leukemia.